SMAD2 and breast carcinoma: Its classical pathway of action activates the TGFβ-Smad signaling pathway mainly through inhibition of Smad7 expression and activation of Smad2 expression and activity [20], and studies in breast cancer have shown that its expression level is negatively correlated with breast cancer stage [21].Wei et al. also concluded that KLF10 inhibits EGFR transcription and the EGFR pathway to suppress breast cancer invasion and metastasis [22].Similar to this study, the researchers established a gene prediction model for CAFs in lung squamous cell carcinoma(LUSC).